Pacira BioSciences will report Q3 financial results on November 6, 2025, followed by a live conference call.
Quiver AI Summary
Pacira BioSciences, Inc. announced it will release its third quarter financial results on November 6, 2025, after U.S. markets close. Following the announcement, the company will host a live conference call and webcast at 4:30 p.m. ET, where participants can register to ask questions. The call will also be available as a webcast on the company’s website, with a replay accessible for two weeks afterward. Pacira is known for its innovative non-opioid pain therapies, including EXPAREL®, ZILRETTA®, and ioveraº®, and is also developing a gene therapy candidate, PCRX-201, aimed at treating common conditions such as osteoarthritis.
Potential Positives
- Pacira BioSciences is set to report its third quarter financial results, anticipating transparency and accountability to its investors.
- The upcoming conference call allows stakeholders to engage directly with company leadership, showcasing a commitment to open communication.
- Pacira continues to lead in the development of innovative, non-opioid pain therapies, addressing a significant need in pain management and enhancing its market position.
- The announcement highlights the company's advanced pipeline, including PCRX-201, which has the potential to impact large prevalent diseases like osteoarthritis, indicating growth and innovation potential.
Potential Negatives
- Potential lack of transparency regarding third quarter financial performance, which may cause concerns among investors.
- Timing of financial results announcement suggests the company may be under pressure to report outcomes that meet investor expectations, heightening scrutiny from the market.
- The ongoing development of PCRX-201 signifies the company's reliance on a pipeline that has not yet proven successful in the market, raising concerns about future revenue streams.
FAQ
When will Pacira announce its third quarter financial results?
Pacira will report its third quarter financial results on November 6, 2025, after U.S. market close.
How can I participate in the Pacira conference call?
Participants can pre-register to join the live conference call and gain access to dial-in information.
Where can I find the live webcast of the financial results?
The live audio of the conference call will be available on the Events page at investor.pacira.com.
Will a replay of the conference call be available?
Yes, a replay of the webcast will be available on the Pacira website for approximately two weeks after the call.
What pain therapies does Pacira offer?
Pacira offers EXPAREL®, ZILRETTA®, and ioveraº®, along with advancing PCRX-201, a gene therapy for osteoarthritis.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PCRX Insider Trading Activity
$PCRX insiders have traded $PCRX stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $PCRX stock by insiders over the last 6 months:
- KRISTEN WILLIAMS (Chief Administrative Officer) sold 14,376 shares for an estimated $377,226
- LAUREN RIKER (Senior Vice President, Finance) sold 5,578 shares for an estimated $146,208
- MARCELO BIGAL sold 4,912 shares for an estimated $116,267
- ABRAHAM CEESAY sold 2,354 shares for an estimated $64,005
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PCRX Hedge Fund Activity
We have seen 114 institutional investors add shares of $PCRX stock to their portfolio, and 119 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC removed 1,330,035 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $31,787,836
- ALYESKA INVESTMENT GROUP, L.P. removed 1,107,240 shares (-84.6%) from their portfolio in Q2 2025, for an estimated $26,463,036
- POLAR CAPITAL HOLDINGS PLC added 910,455 shares (+inf%) to their portfolio in Q2 2025, for an estimated $21,759,874
- UBS GROUP AG added 607,057 shares (+143.9%) to their portfolio in Q2 2025, for an estimated $14,508,662
- BALYASNY ASSET MANAGEMENT L.P. added 565,288 shares (+36.1%) to their portfolio in Q2 2025, for an estimated $13,510,383
- AMERICAN CENTURY COMPANIES INC added 515,090 shares (+77.2%) to their portfolio in Q2 2025, for an estimated $12,310,651
- ECOR1 CAPITAL, LLC added 457,471 shares (+inf%) to their portfolio in Q2 2025, for an estimated $10,933,556
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PCRX Analyst Ratings
Wall Street analysts have issued reports on $PCRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 05/09/2025
To track analyst ratings and price targets for $PCRX, check out Quiver Quantitative's $PCRX forecast page.
Full Release
BRISBANE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its third quarter financial results after the close of the U.S. markets on Thursday November 6, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET.
For listeners who wish to participate in the question and answer session via telephone, please pre-register here . All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at investor.pacira.com . For those unable to participate in the live call, a replay of the webcast will be available on the Pacira website for approximately two weeks following the call.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL ® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA ® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº ® , a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com .
Investor Contact:
Pacira BioSciences, Inc.
Christian Pedetti, (973) 254-4387
[email protected]
